{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:27:40Z","timestamp":1785569260334,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00432-023-05321-w","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T17:02:27Z","timestamp":1692982947000},"page":"15095-15102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1\u2009\u2265\u200950% advanced non small cell lung cancer"],"prefix":"10.1007","volume":"149","author":[{"given":"H\u00e9l\u00e8ne","family":"Doubre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Justeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ricordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Swalduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bylicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Auliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bigay-Game","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Pinsolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Amrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Descourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"5321_CR1","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/cam4.2806","volume":"9","author":"K Amrane","year":"2020","unstructured":"Amrane K, Geier M, Corre R, L\u00e9na H, L\u00e9veiller G, Gadby F et al (2020) First-line pembrolizumab for non-small cell lung cancer patients with PD-L1\u00a0\u226550% in a multicenter real-life cohort: The PEMBREIZH study. Cancer Med. 9:2309\u20132316. https:\/\/doi.org\/10.1002\/cam4.2806","journal-title":"Cancer Med."},{"key":"5321_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"5321_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"5321_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002332","author":"JU Choi","year":"2021","unstructured":"Choi JU, Lee NK, Seo H et al (2021) Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002332","journal-title":"J Immunother Cancer"},{"key":"5321_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.thromres.2021.06.018","volume":"205","author":"X Deschenes-Simard","year":"2021","unstructured":"Deschenes-Simard X, Richard C, Galland L et al (2021) Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. Thromb Res 205:29\u201339. https:\/\/doi.org\/10.1016\/j.thromres.2021.06.018","journal-title":"Thromb Res"},{"key":"5321_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03232-2","author":"R Descourt","year":"2022","unstructured":"Descourt R, Greillier L, Perol M et al (2022) First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score >\/= 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-022-03232-2","journal-title":"Cancer Immunol Immunother"},{"key":"5321_CR7","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","volume":"118","author":"JH Foley","year":"2016","unstructured":"Foley JH, Conway EM (2016) Cross talk pathways between coagulation and inflammation. Circ Res 118:1392\u20131408. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.306853","journal-title":"Circ Res"},{"key":"5321_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.thromres.2017.03.024","volume":"154","author":"HE Fuentes","year":"2017","unstructured":"Fuentes HE, Oramas DM, Paz LH, Casanegra AI, Mansfield AS, Tafur AJ (2017) Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thromb Res 154:28\u201334. https:\/\/doi.org\/10.1016\/j.thromres.2017.03.024","journal-title":"Thromb Res"},{"key":"5321_CR9","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1007\/s00520-021-06139-3","volume":"29","author":"DC Guven","year":"2021","unstructured":"Guven DC, Aksun MS, Sahin TK et al (2021) Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Support Care Cancer 29:5417\u20135423. https:\/\/doi.org\/10.1007\/s00520-021-06139-3","journal-title":"Support Care Cancer"},{"key":"5321_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809\u2013815. https:\/\/doi.org\/10.1001\/archinte.160.6.809","journal-title":"Arch Intern Med"},{"key":"5321_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"5321_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.thromres.2021.10.014","volume":"208","author":"H Hill","year":"2021","unstructured":"Hill H, Robinson M, Lu L, Slaughter D, Amin A, Mileham K, Patel JN (2021) Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. Thromb Res 208:71\u201378. https:\/\/doi.org\/10.1016\/j.thromres.2021.10.014","journal-title":"Thromb Res"},{"key":"5321_CR13","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jth.15272","volume":"19","author":"O Icht","year":"2021","unstructured":"Icht O, Darzi N, Shimony S et al (2021) Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Haemost 19:1250\u20131258. https:\/\/doi.org\/10.1111\/jth.15272","journal-title":"J Thromb Haemost"},{"key":"5321_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2022.10.005","volume":"174","author":"G Justeau","year":"2022","unstructured":"Justeau G, Huchot E, Simonneau Y, Roa M, Le Treut J, Le Garff G et al (2022) Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. Lung Cancer 174:45\u201349","journal-title":"Lung Cancer"},{"key":"5321_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632\u2013634. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x","journal-title":"J Thromb Haemost"},{"key":"5321_CR16","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902\u20134907. https:\/\/doi.org\/10.1182\/blood-2007-10-116327","journal-title":"Blood"},{"key":"5321_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1634\/theoncologist.2017-0205","volume":"23","author":"NM Kuderer","year":"2018","unstructured":"Kuderer NM, Poniewierski MS, Culakova E et al (2018) Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). Oncologist 23:247\u2013255. https:\/\/doi.org\/10.1634\/theoncologist.2017-0205","journal-title":"Oncologist"},{"key":"5321_CR18","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik F, Chan WE, Wiedemann S et al (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137:1669\u20131678. https:\/\/doi.org\/10.1182\/blood.2020007878","journal-title":"Blood"},{"key":"5321_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","volume":"104","author":"FI Mulder","year":"2019","unstructured":"Mulder FI, Candeloro M, Kamphuisen PW et al (2019) The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 104:1277\u20131287. https:\/\/doi.org\/10.3324\/haematol.2018.209114","journal-title":"Haematologica"},{"key":"5321_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010067","author":"F Nichetti","year":"2019","unstructured":"Nichetti F, Ligorio F, Zattarin E et al (2019) Is There an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12010067","journal-title":"Cancers (Basel)"},{"key":"5321_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.amjmed.2021.01.031","volume":"134","author":"AG Ording","year":"2021","unstructured":"Ording AG, Skjoth F, Sogaard M, Hojen AA, Overvad TF, Noble S, Goldhaber SZ, Larsen TB (2021) Increasing incidence and declining mortality after cancer-associated venous thromboembolism: a nationwide cohort study. Am J Med. 134:868\u2013876865. https:\/\/doi.org\/10.1016\/j.amjmed.2021.01.031","journal-title":"Am J Med."},{"key":"5321_CR22","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"5321_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"5321_CR24","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.21037\/jtd.2017.11.116","volume":"9","author":"Q Shen","year":"2017","unstructured":"Shen Q, Dong X, Tang X, Zhou J (2017) Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study. J Thorac Dis 9:5068\u20135074. https:\/\/doi.org\/10.21037\/jtd.2017.11.116","journal-title":"J Thorac Dis"},{"key":"5321_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/archinte.158.6.585","volume":"158","author":"MD Silverstein","year":"1998","unstructured":"Silverstein MD, Heit JA, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585\u2013593. https:\/\/doi.org\/10.1001\/archinte.158.6.585","journal-title":"Arch Intern Med"},{"key":"5321_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/CIRCULATIONAHA.114.009107","volume":"130","author":"KK Sogaard","year":"2014","unstructured":"Sogaard KK, Schmidt M, Pedersen L, Horvath-Puho E, Sorensen HT (2014) 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 130:829\u2013836. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.009107","journal-title":"Circulation"},{"key":"5321_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ajco.12770","volume":"14","author":"KZ Thein","year":"2018","unstructured":"Thein KZ, Yeung SJ, Oo TH (2018) Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials (RCTs). Asia Pac J Clin Oncol 14:210\u2013216. https:\/\/doi.org\/10.1111\/ajco.12770","journal-title":"Asia Pac J Clin Oncol"},{"key":"5321_CR28","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-l1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5:1008\u20131019. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393","journal-title":"JAMA Oncol"},{"key":"5321_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","volume":"18","author":"F Zhou","year":"2021","unstructured":"Zhou F, Qiao M, Zhou C (2021) The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol 18:279\u2013293. https:\/\/doi.org\/10.1038\/s41423-020-00577-5","journal-title":"Cell Mol Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05321-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T11:20:51Z","timestamp":1698319251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05321-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5321"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05321-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"4 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflicts of interest\/Competing interests: L. Greillier reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Roche, Sanofi Aventis, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, Novartis, Pfizer, Takeda, Bayer and Amgen, outside the submitted work. C. Chouaid reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, Novartis, Pfizer, Takeda, Bayer and Amgen, outside the submitted work. C. Decroisette reports personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Roche, Sanofi Aventis, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, Novartis, Pfizer, Takeda, and Amgen, outside the submitted work. M. P\u00e9rol reports personal fees and non-financial support from Roche, Eli Lilly, Pfizer, Boehringer Ingelheim, Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, AstraZeneca, Takeda, Gritstone, Sanofi, GlaxoSmithKline, Amgen, Chugai, Illumina, Da\u00efchi-Sankyo and Abbvie outside the submitted work. R. Descourt reports personal fees and non-financial support from AstraZeneca, Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Takeda, and Chugai, outside the submitted work. C. Ricordel, J.B. Auliac, L. Falchero, R. Gervais, R. Veillon, S. Vieillot, F. Guisier, M. Marcq, G. Justeau, L. Bigay-Game, M. Bernardi, P. Fournel, H. Doubre, J. Pinsolle and K. Amrane report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"L. Greillier reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Roche, Sanofi Aventis, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, Novartis, Pfizer, Takeda, Bayer and Amgen, outside the submitted work. C. Chouaid reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, Novartis, Pfizer, Takeda, Bayer and Amgen, outside the submitted work. C. Decroisette reports personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Roche, Sanofi Aventis, Bristol-Myers Squibb, Merck Sharp & Dohme, Lilly, Novartis, Pfizer, Takeda, and Amgen, outside the submitted work. M. P\u00e9rol reports personal fees and non-financial support from Roche, Eli Lilly, Pfizer, Boehringer Ingelheim, Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, AstraZeneca, Takeda, Gritstone, Sanofi, GlaxoSmithKline, Amgen, Chugai, Illumina, Da\u00efchi-Sankyo and Abbvie outside the submitted work. R. Descourt reports personal fees and non-financial support from AstraZeneca, Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Takeda, and Chugai, outside the submitted work. C. Ricordel, J.B. Auliac, L. Falchero, R. Gervais, R. Veillon, S. Vieillot, F. Guisier, M. Marcq, G. Justeau, L. Bigay-Game, M. Bernardi, P. Fournel, H. Doubre, J. Pinsolle and K. Amrane report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by a national independent Ethics Committee (2019-A02073-54; December 11, 2019).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients received written and oral information on the study and gave their consent to participate in the study and for the use of their medical data for research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}